Key facts
- Prolific Machines’s last known valuation is $202.0M.
- It has raised $96.6M across 1 recorded rounds; the latest was Later Stage VC ($54.6M) in May 2024.
- Notable investors include SOSV, In-Q-Tel, IndieBio, University of California, Breakthrough Energy — 42 tracked in total.
- Prolific Machines has filed 1 Form D with the SEC, most recently May 2024 ($54.6M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 42 names
- ·Watchlist + deal alerts for Prolific Machines
Funding rounds
1 roundsAbout Prolific Machines
Developer of a biologics manufacturing platform designed to improve therapeutic protein production for biotechnology and pharmaceutical companies. The company offers optogenetic tools combined with proprietary closed-loop control, enabling early-stage biotech firms and pharma partners to optimize cell line development, bioprocessing, and preclinical manufacturing with greater precision and efficiency.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2020
- Employees
- 55
- Website
- prolific-machines.com/
- Ownership
- Privately Held (backing)
Prolific Machines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prolific Machines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prolific Machines in its N-PORT filings yet. We sweep new filings monthly.